AlzProtect pens Parexel brain disease pact using new Biotech division

purple brain
The pair will work together on a midstage test for progressive supranuclear palsy. (Raman Oza / Pixabay)

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy (PSP).

The Lille, France-based company will use Parexel for its PSP trial, which is a rare degenerative disease of the brain that causes serious problems with walking, balance and eye movements, using the CRO for work from protocol writing to the coordination of patient recruitment.

It will tap into Parexel’s new “Biotech” unit, a dedicated division launched in January to “support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.”

Webinar

Lipid-based Formulations for Early Stage Clinical Trials

Liquid-filled capsule technology has a proven record for addressing complex API formulation challenges, but also offers a simple and effective pathway to the clinic. Register now to learn more about lipid-based formulations.

RELATED: Parexel, on a hiring spree, nabs another key FDA staffer as it bolsters oncology executives

“It was important for us to work with an internationally renowned partner covering the full range of needs for our first phase 2a clinical trial,” said Philippe Verwaerde, president and scientific director of AlzProtect.

“AlzProtect is committed to achieving Phase 2a results in complete confidence. With PAREXEL Biotech, we now have access to the expertise necessary to achieve this goal,” said Laurent Dupire, COO of AlzProtect.

“PAREXEL’S recently launched Biotech unit delivers innovative, customized offerings to the biotech community, building on our more than 20 years of experience in this area,” said Jim Anthony, global head of Biotech, Parexel.  

“Our collaboration with AlzProtect is a great example of how we can work together in a unique way, and we look forward to helping advance this important rare disease initiative.”

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.